Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropriate" of the WHO as "the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance".
|Numero di pagine||12|
|Rivista||EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES|
|Stato di pubblicazione||Published - 2014|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
Scichilone, N., Blasi, Di Marco, F., Braido, F., & Santus, P. (2014). The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 18, 321-332.